American Association for Cancer Research to Induct the 2014 Elected Class of Fellows of the AACR Academy

PHILADELPHIA — The American Association for Cancer Research (AACR) will formally induct its 2014 class of elected fellows of the AACR Academy at the AACR Annual Meeting 2014, held in San Diego, Calif., April 5-9.

The AACR Academy has been created to recognize and honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer. The fellows have been elected through a rigorous peer-review process that evaluates individuals on the basis of their stellar scientific achievements in cancer research.

“Our 2014 class of fellows includes a number of the most prestigious laboratory researchers and physician-scientists who have contributed enormously to the cancer field. We look forward to celebrating their fundamental discoveries and contributions at this year’s annual meeting,” said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR.

The AACR Academy is an entity within the AACR that recognizes those individuals who have made exceptional contributions to cancer research and/or cancer-related biomedical science. Only scientists whose work has had a major impact on the field are eligible for election as a fellow.

This collection of stellar global leaders in cancer research will offer invaluable insights into the future of cancer research and cancer-related biomedical science, as well as continue to work with the AACR in its mission to prevent and cure all cancers.

The 2014 class of fellows will be inducted into the AACR Academy on Friday, April 4, at the U.S. Grant Hotel in San Diego, Calif., at 6:30 p.m. PT. This induction ceremony will be followed by a meeting of Academy members on Saturday, April 5, and a special recognition of the elected 2014 fellows during the opening plenary session of the annual meeting on Sunday morning, April 6.

Members of the 2014 class of fellows of the AACR Academy are:

• Jerry Adams, Ph.D., joint head of the Molecular Genetics of Cancer Division and director of the Leukemia and Lymphoma Society Specialized Center of Research, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
• James P. Allison, Ph.D., professor and chair of the Department of Immunology, director of the Immunology Platform, and deputy director of the David H. Koch Center for Applied Research in Genitourinary Cancers, Department of Genitourinary Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
• Mariano Barbacid, Ph.D., professor of molecular oncology, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
• José Baselga, M.D., Ph.D., physician-in-chief, Memorial Sloan Kettering Cancer Center, New York, N.Y.
• Stephen B. Baylin, M.D., deputy director and associate director for research, Sidney Kimmel Comprehensive Cancer Center; Virginia and D.K. Ludwig professor for cancer research and medicine and chief of the Cancer Biology Division, Johns Hopkins University School of Medicine, Baltimore, Md.
• Günter Blobel, M.D., Ph.D., John D. Rockefeller Jr. professor, Laboratory of Cell Biology, The Rockefeller University, New York, N.Y.; investigator, Howard Hughes Medical Institute
• David Botstein, Ph.D., Anthony B. Evnin professor of genomics, Princeton University, Princeton, N.J.; chief scientific officer, Calico, San Francisco, Calif.
• Joan S. Brugge, Ph.D., Louise Foote Pfeiffer professor of cell biology and chair of the Department of Cell Biology, Harvard Medical School, Boston, Mass.
• Lewis C. Cantley, Ph.D., Margaret and Herman Sokol professor and director of the Meyer Cancer Center, Weill Cornell Medical College, affiliated with New York-Presbyterian Hospital, New York, N.Y.
• Pierre Chambon, M.D., honorary professor, Collège-de-France; professor of molecular biology and genetics, Institute for Advanced Study, University of Strasbourg; group leader, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch-Graffenstaden, Strasburg, France
• Hans Clevers, M.D., Ph.D., professor in medical genetics, University of Utrecht; president of the Royal Netherlands Academy of Arts and Sciences, Hubrecht Institute, Utrecht, Netherlands
• James E. Darnell Jr., M.D., Vincent Astor professor emeritus and head, Laboratory of Molecular Cell Biology, The Rockefeller University, New York, N.Y.
• Titia de Lange, Ph.D., Leon Hess professor, American Cancer Society research professor, and director of the Anderson Center for Cancer Research, The Rockefeller University, New York, N.Y.
• Vincent T. DeVita Jr., M.D., Amy and Joseph Perella professor of medicine, Yale Cancer Center; professor of epidemiology and public health, Yale Medical School, New Haven, Conn.
• Lawrence H. Einhorn, M.D., distinguished professor of medicine and Lance Armstrong Foundation professor of medicine, Indiana University School of Medicine, Indianapolis, Ind.
• Stephen J. Elledge, Ph.D., Gregor Mendel professor of genetics and medicine, Department of Genetics, Harvard Medical School, Division of Genetics, Brigham and Women’s Hospital, Boston, Mass.
• Ronald M. Evans, Ph.D., professor and director of the Gene Expression Laboratory and March of Dimes chair in molecular and developmental biology, The Salk Institute for Biological Studies, La Jolla, Calif.; investigator, Howard Hughes Medical Institute
• Andrew Z. Fire, Ph.D., Departments of Pathology and Genetics, George D. Smith professor in molecular and genetic medicine, Stanford University School of Medicine, Stanford, Calif.
• Emil J Freireich, M.D., Ruth Harriet Ainsworth chair, distinguished teaching professor, director of the Adult Leukemia Research Program, and director of the Special Medical Education Programs, The University of Texas MD Anderson Cancer Center, Houston, Texas
• Robert C. Gallo, M.D., Homer and Martha Gudelsky distinguished professor of medicine, professor of medicine and of microbiology and immunology, and director of the Institute of Human Virology, University of Maryland School of Medicine, College Park, Md.
• Douglas Hanahan, Ph.D., director of the Swiss Institute for Experimental Cancer Research, Swiss Federal Institute of Technology Department of Life Sciences, Lausanne, Switzerland
• Richard O. Hynes, Ph.D., Daniel K. Ludwig professor for cancer research, Massachusetts Institute of Technology, Cambridge, Mass.; investigator, Howard Hughes Medical Institute
• William G. Kaelin Jr., M.D., professor of medicine, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Mass.; investigator, Howard Hughes Medical Institute
• Kenneth W. Kinzler, Ph.D., professor of oncology and director of the Ludwig Center, Johns Hopkins University, Johns Hopkins Kimmel Cancer Center, Baltimore, Md.
• Richard D. Kolodner, Ph.D., member and head of the Laboratory of Cancer Genetics, Ludwig Institute for Cancer Research; distinguished professor in the Departments of Medicine and Cellular and Molecular Medicine, University of California, San Diego School of Medicine, San Diego, Calif.
• Ronald Levy, M.D., Robert K. and Helen K. Summy professor of medicine, Stanford University School of Medicine, Palo Alto, Calif.
• Frederick P. Li, M.D., professor of clinical cancer epidemiology emeritus, Harvard School of Public Health; professor of medicine emeritus, Dana-Farber Cancer Institute, Boston, Mass.
• David M. Livingston, M.D., deputy director of the Dana-Farber Cancer Institute, chief of the Charles A. Dana Division of Human Cancer Genetics, and Emil Frei professor of genetics and medicine, Harvard Medical School, Boston Mass.
• Paul A. Marks, M.D., president emeritus, Memorial Sloan Kettering Cancer Center, New York, N.Y.
• Peter C. Nowell, M.D., Gaylord P. and Mary Louise Harnwell professor emeritus in the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa.
• Christiane Nüsslein-Volhard, Ph.D., director of the Department of Genetics, Max Planck Institute for Developmental Biology, Tübingen, Germany
• Sir Richard Peto, FRS, professor of medical statistics and epidemiology, University of Oxford, Oxford, United Kingdom
• Charles L. Sawyers, M.D., chairperson of the Human Oncology and Pathogenesis Program and member at Memorial Sloan Kettering Cancer Center; professor, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, N.Y.; investigator, Howard Hughes Medical Institute
• Sir Michael R. Stratton, MBBS, Ph.D., director, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
• Axel Ullrich, Ph.D., director of the Department of Molecular Biology, Max Planck Institute of Biochemistry, Munich, Germany
• Inder M. Verma, Ph.D., Irwin and Joan Jacobs chair in exemplary life science and American Cancer Society professor of molecular biology, The Salk Institute for Biological Sciences, La Jolla, Calif.
• Irving L. Weissman, M.D., director of the Institute for Stem Cell Biology and Regenerative Medicine, director of the Stanford Ludwig Center for Cancer Stem Cell Research and Medicine, and professor of pathology and developmental biology, Stanford University School of Medicine, Palo Alto, Calif.
• Owen N. Witte, M.D., director of the Broad Stem Cell Research Center and distinguished professor of microbiology, immunology, and molecular genetics, University of California, Los Angeles, Calif.; investigator at Howard Hughes Medical Institute

#AACR14

Advertisement